Trials / Completed
CompletedNCT04876495
The Effects of Whey, Rice and Potato pRotein isOlates on appeTite rEgulatIoN in Healthy Men
Comparative Effects of Dairy and Plant-based Protein Intake on Acute Glucose Homeostasis and Appetite Regulation in Healthy Men
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- University of Westminster · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. The additional intake of protein often occurs in the form of supplements. One of the main ingredients used in sports and weight loss supplements are animal-derived proteins such as whey, which are of high quality, containing all the essential amino acids required in human nutrition with a high absorption rate. However, whey protein has a high environmental footprint, and it may contribute to insulin resistance in susceptible groups (e.g. obese, T2DM, insulin resistant, or those with sarcopenic obesity). Rice and potato protein isolates are high-quality plant proteins containing all essential amino acids comparably to whey protein. These plant-derived proteins may provide a more sustainable and accessible alternative to animal-derived proteins for appetite regulation and weight management.
Detailed description
Intervention study with three treatment groups in a randomised, single-blind, triple crossover design. Study population: Healthy male participants will receive three different isocaloric and -volumetric protein shakes prepared using whey, rice and potato protein powders on different trial days with at least a one-week washout period apart. Biological samples (blood and saliva samples) are collected at various time points during the visit. Blood samples are collected at baseline 10 min prior (T-10), then at 30 min (T30), 60 min (T60), 120 min (T120) and at 180 min (T180) after protein shake consumption. Saliva samples are collected at baseline (T-10), then at every 30 minutes following protein shake consumption (T30, T60, T90, T120, T150, T180). In addition, pertinent questionnaires Visual Analogue Scale \[VAS\] for the assessment of satiety and VAS for the assessment of protein shakes' perception will be collected at T-10, T30, T60, T90, T120, T150, T180 and at T0, respectively
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Whey protein isolate | Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the whey protein shake: * Tropicana Trop50 Orange Juice 207mL * Water 43 mL * Sucralose 0.5g The total energy 233.47Kcal. Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study. |
| DIETARY_SUPPLEMENT | Potato protein isolate | Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake. Other ingredients in the potato protein shake: * Tropicana Trop50 Orange Juice 250mL * Sucralose 0.5g The total energy 233.46Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study. |
| DIETARY_SUPPLEMENT | Rice protein isolate | Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the rice protein shake: * Tropicana Trop50 Orange Juice 183mL * Water 67mL * Sucralose 0.5g The total energy 233.43Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study. |
Timeline
- Start date
- 2018-07-20
- Primary completion
- 2021-02-19
- Completion
- 2021-02-19
- First posted
- 2021-05-06
- Last updated
- 2021-05-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04876495. Inclusion in this directory is not an endorsement.